PA-PPG
24.5.2022 14:33:14 CEST | Business Wire | Press release
PPG (NYSE:PPG) today announced that it has committed to setting near-term company-wide emission reductions in line with climate science through the Science Based Target initiative (SBTi), which is an organization that helps companies define their decarbonization strategy and reduce the impacts of climate change.
PPG has an existing goal to reduce GHG emissions intensity by 15% by 2025 from a 2017 baseline, achieving a 9.7% reduction in 2021. The company has long reported emissions intensity from its own operations (Scope 1 emissions) and purchased electricity, steam, heating and cooling (Scope 2 emissions) and plans to unveil its new 2030 goals over the coming months. Moving forward, PPG is prioritizing evaluating indirect emissions that are from sources outside of the organization that PPG does not own or control, including raw materials, use of sold products, and product end-of-life (Scope 3 emissions).
“In this critical moment for climate change, we are committed to further evaluating and reducing emissions throughout our value chain,” said Diane Kappas, PPG vice president, Global Sustainability. “We are working across our organization to define additional actions we can take to help prevent the earth from warming more than 1.5 degrees Celsius. Following our validation work with SBTi and an emissions analysis, we intend to announce new, aggressive 2030 goals that will define our decarbonization strategy to help protect the planet for current and future generations.”
PPG also released its 2021 Environmental, Social and Governance (ESG) Report, which details advancements in its sustainable innovations, board governance of ESG, efforts to reach its 2025 sustainability goals and further actions to support customers’ sustainability goals. The full report is available at sustainability.ppg.com .
“Sustainability is at the heart of our purpose to protect and beautify the world,” said Kappas. “Our employees’ hard work and dedication helped us meet and surpass several of our near-term 2025 goals, and we continue to look for additional ways to reduce our emissions and overall environmental impact. While we are proud of our achievements, we recognize that now is the time for further action. We look forward to unveiling science-based targets as we complete the validation process.”
The latest report highlights PPG’s environmental actions and innovations globally. Key highlights include:
- Introduced PPG ERGOLUXE™ powder coatings, which offer first-pass transfer efficiency rates of up to 85% and the ability to reuse overspray. PPG ErgoLuxe Eco contains up to 13% recycled polyethylene terephthalate (rPET). Since 2017, PPG has used more than 6 million pounds of rPET to manufacture its coatings.
- Launched COMEX® TOP paint by PPG, which contributes to the circular economy by incorporating recycled tires, saving more than 270,000 tires from landfills since the product was introduced in 2021. The product is intended for application on roofs and provides thermal insulation, resulting in emissions reduction through energy savings.
- Implemented the Zero Discharge Project at Architectural Coatings facilities in the U.S. and Canada, enabling PPG to recycle and reuse more than 1.7 million gallons of water in its manufacturing process over the past two years.
- Installed a combined heat and power (CHP) unit at the Caivano, Italy, facility, creating an efficiency improvement equating to an annual reduction of approximately 1,100 metric tons of carbon dioxide (CO2 ).
- Invested more than $8.7 million between 2015 and 2021 in PPG’s global COLORFUL COMMUNITIES® initiative.
In 2021, PPG reduced process waste, increased renewable energy use in its facilities and increased sales from sustainably advantaged products. Highlights include:
- 38% of sales from sustainably advantaged products against the goal of 40% by 2025;
- 24% of electricity usage from renewable energy sources against the goal of 25% by 2025;
- 40% of manufacturing and research and development facilities with zero process waste to landfill, above the goal of 35% by 2025; and
- 37% reduction in waste disposal intensity from the 2017 baseline, above the goal of 25% by 2025.
To create strong and equitable communities, PPG worked to engage employees and diversify its recruiting and talent pools. Efforts focused on diversity, equity and inclusion (DE&I) include:
-
Unveiled new DE&I commitments:
- Achieve 34% to 36% representation of non-frontline global female professionals by 2025. PPG achieved 30% as of December 31, 2021.
- Increase representation of Black, Latino and Asian employees by 45% to 55% across our non-frontline, U.S.-based employee population (using January 1, 2021, as our baseline). At the end of 2021, PPG increased non-frontline Black employees by 13%, Latino employees by 9% and Asian employees by 8%.
- Achieve total global employee resource network (ERN) and DE&I capability-building participation of 50% by 2025. As of the end of 2021, PPG achieved 33% of this goal.
- Published the first PPG DE&I Report .
- Grew eight global ERNs to include more than 7,000 employee members across more than 60 countries.
- Invested $7.4 million through 2021 to advance racial equity in the U.S. by funding educational pathways for Black communities and people of color.
PPG’s 2021 reporting disclosures align with the Global Reporting Initiative (GRI) Standards and the Sustainability Accounting Standards Board (SASB) chemical standard. The company also strengthened its reporting against the United Nations Sustainable Development Goals (UN SDGs) and reported qualitative climate-related risks according to the Task Force on Climate-Related Financial Disclosures (TCFD).
To learn more about ESG at PPG and explore the report, visit sustainability.ppg.com .
PPG: WE PROTECT AND BEAUTIFY THE WORLD™
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for nearly 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 75 countries and reported net sales of $16.8 billion in 2021. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com .
We protect and beautify the world and ErgoLuxe are trademarks and Colorful Communities and the PPG Logo are registered trademarks of PPG Industries Ohio, Inc.
Comex is a registered trademark of Consorcio Comex, S.A. de C.V.
CATEGORY Sustainability
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
